Related Experiment Video

Updated: Sep 30, 2026

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

Angiotensin-converting enzyme gene insertion/deletion polymorphism in Kuwaiti children with retinopathy of

M Z Haider1, L V Devarajan, M Al-Essa

  • 1Paediatrics Department, Faculty of Medicine, Kuwait University, Kuwait. haider@hsc.kuniv.edu.kw

Biology of the Neonate
|August 10, 2002
PubMed

Insights

The angiotensin-converting enzyme (ACE) II genotype is linked to a higher risk of retinopathy of prematurity (ROP) in premature infants. The DD genotype is associated with advanced ROP stages, indicating disease progression.

Area of Science:

  • Ophthalmology
  • Genetics
  • Neonatology

Background:

  • Retinopathy of prematurity (ROP) is a neovascular disease affecting premature infants, potentially causing blindness.
  • Some ROP cases advance to severe stages despite treatment.
  • The angiotensin-converting enzyme (ACE) gene insertion/deletion (I/D) polymorphism is studied for its role in various conditions.

Purpose of the Study:

  • To investigate the association between ACE gene I/D polymorphism and the risk and progression of ROP in premature Kuwaiti infants.

Main Methods:

  • Genotyping for ACE I/D polymorphism was performed using PCR on 181 premature infants.
  • Infants were categorized into ROP cases (n=74) and non-ROP controls (n=107).
  • ROP cases were further divided into spontaneously regressing (stages 1-3) and advanced (stages 4-5) subgroups.

Main Results:

  • The II genotype was more frequent in ROP cases than controls (p < 0.01).
  • The DD genotype was significantly higher in advanced ROP cases compared to those with spontaneously regressing ROP (p < 0.04).
  • No significant differences in ID and II genotypes were observed between ROP subgroups.

Conclusions:

  • The ACE II genotype may increase susceptibility to developing ROP.
  • The ACE DD genotype is associated with the progression of ROP to advanced stages.
  • ACE gene polymorphism warrants further investigation in the context of ROP pathogenesis and severity.

More Related Videos

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

CRISPR/Cas9 Ribonucleoprotein-mediated Precise Gene Editing by Tube Electroporation08:31

CRISPR/Cas9 Ribonucleoprotein-mediated Precise Gene Editing by Tube Electroporation

Published on: June 20, 2019

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Alternative RNA Splicing02:18

Alternative RNA Splicing

Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...